{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T02:03:23Z","timestamp":1760061803983},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:p>The aim of this study was to assess the prognostic importance of lymph node ratio (LNR) in stage III melanoma after complete lymph nodal dissections. From European Organization for Research and Treatment of Cancer randomized trials 18871, 18952, and 18991, 2358 patients had full information on positive and examined lymph nodes (LNs) and were included. Cox proportional hazards models stratified by trial were used to assess the prognostic impact of LNR adjusted for confounders on melanoma-specific survival. Optimal cutoff values for LNR were calculated for each LN dissection site (axillary, inguinal, and neck). LNR (\u2265 vs. &lt;35%: hazard ratio=1.44, 95% confidence interval: 1.23\u20131.69) and number of positive LNs appeared to be of independent strong prognostic importance. Dissection sites impacted the optimal LNR cutoff: 35% for axillary, 40% for inguinal, and 50% for neck dissections. Combining these into one \u2018high versus low LNR\u2019 resulted in a highly significant multivariately adjusted hazard ratio of 1.48 (95% confidence interval: 1.26\u20131.74). In subgroup analyses, LNR was only significant in advanced disease (American Joint Committee on Cancer stage N2b, N3; IIIC). LNR was most significant for inguinal dissections, followed by axillary dissections, but seemed less useful in neck dissections. LNR is an independent significant prognostic factor in stage III melanoma patients. Our study showed higher than previously reported cutoffs that differed per dissection site. However, because of conflicting results compared with other studies and apparent limited prognostic impact confined to subgroups, the practical use of LNR seems limited.<\/jats:p>","DOI":"10.1097\/cmr.0000000000000433","type":"journal-article","created":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T16:57:39Z","timestamp":1518195459000},"page":"222-229","source":"Crossref","is-referenced-by-count":5,"title":["Lymph node ratio as a prognostic factor in melanoma: results from European Organization for Research and Treatment of Cancer 18871, 18952, and 18991 studies"],"prefix":"10.1097","volume":"28","author":[{"given":"Alessandro A.","family":"Testori","sequence":"first","affiliation":[{"name":"European Organization for Research and Treatment of Cancer Melanoma Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Suciu","sequence":"additional","affiliation":[{"name":"European Organization for Research and Treatment of Cancer (EORTC)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander C.J.","family":"van Akkooi","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Netherlands Cancer Institute \u2013 Antoni van Leeuwenhoek, Amsterdam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariano","family":"Suppa","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Erasmus Hospital, Free University, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander M.M.","family":"Eggermont","sequence":"additional","affiliation":[{"name":"Gustave Roussy Oncology Institute, Villejuif\/Paris-Sud, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"de Vries","sequence":"additional","affiliation":[{"name":"Department of Public Health, Erasmus University Medical Center, Rotterdam"},{"name":"Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine, Pontifical Javeriana University, Bogota, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjen","family":"Joosse","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230902","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1245\/s10434-011-2012-9","article-title":"Lymph node ratio should be considered for incorporation into staging for breast cancer","volume":"18","author":"Chagpar","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"R2-20230902","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1245\/s10434-011-2189-y","article-title":"Prognostic value of number of removed lymph nodes, number of involved lymph nodes, and lymph node ratio in 7502 breast cancer patients enrolled onto trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG)","volume":"19","author":"Tausch","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"R3-20230902","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.ejca.2008.05.011","article-title":"The number of positive nodes and the ratio of positive to excised nodes are significant predictors of survival in women with micrometastatic node-positive breast cancer","volume":"44","author":"Truong","year":"2008","journal-title":"Eur J Cancer"},{"key":"R4-20230902","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/ejso.2002.1239","article-title":"Axillary lymph node ratio and total number of removed lymph nodes: predictors of survival in stage I and II breast cancer","volume":"28","author":"Van der Wal","year":"2002","journal-title":"Eur J Surg Oncol"},{"key":"R5-20230902","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1200\/JCO.2008.18.6965","article-title":"Lymph node ratio as an alternative to pN staging in node-positive breast cancer","volume":"27","author":"Vinh-Hung","year":"2009","journal-title":"J Clin Oncol"},{"key":"R6-20230902","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1200\/JCO.2003.07.010","article-title":"Effect of number of lymph nodes sampled on outcome in patients with stage I non-small-cell lung cancer","volume":"21","author":"Gajra","year":"2003","journal-title":"J Clin Oncol"},{"key":"R7-20230902","doi-asserted-by":"crossref","first-page":"8706","DOI":"10.1200\/JCO.2005.02.8852","article-title":"Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes","volume":"23","author":"Berger","year":"2005","journal-title":"J Clin Oncol"},{"key":"R8-20230902","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1245\/s10434-010-1158-1","article-title":"Prognostic value of the lymph node ratio in stage III colorectal cancer: a systematic review","volume":"17","author":"Ceelen","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"R9-20230902","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1245\/s10434-007-9716-x","article-title":"Lymph node ratio: role in the staging of node-positive colon cancer","volume":"15","author":"Wang","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"R10-20230902","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/SLA.0b013e3181f9b8b6","article-title":"Lymph node ratio provides prognostic information in addition to American Joint Committee on Cancer N stage in patients with melanoma, even if quality of surgery is standardized","volume":"253","author":"Spillane","year":"2011","journal-title":"Ann Surg"},{"key":"R11-20230902","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1002\/cncr.24290","article-title":"Lymph node ratio predicts disease-specific survival in melanoma patients","volume":"115","author":"Xing","year":"2009","journal-title":"Cancer"},{"key":"R12-20230902","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jss.2012.08.050","article-title":"The lymph node ratio has limited prognostic significance in melanoma","volume":"179","author":"Egger","year":"2013","journal-title":"J Surg Res"},{"key":"R13-20230902","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1245\/s10434-007-9641-z","article-title":"N-ratio: a novel independent prognostic factor for patients with stage-III cutaneous melanoma","volume":"15","author":"Rossi","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"R14-20230902","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/jso.22051","article-title":"Lymph node ratio is an important and independent prognostic factor for patients with stage III melanoma","volume":"105","author":"Berger","year":"2012","journal-title":"J Surg Oncol"},{"key":"R15-20230902","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1245\/s10434-010-1208-8","article-title":"The prognostic significance of nonsentinel lymph node metastasis in melanoma","volume":"17","author":"Brown","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"R16-20230902","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1245\/s10434-013-3186-0","article-title":"Limitations of lymph node ratio, evidence-based benchmarks, and the importance of a thorough lymph node dissection in melanoma","volume":"20","author":"Grotz","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"R17-20230902","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.surg.2011.02.021","article-title":"Validation of the prognostic value of lymph node ratio in patients with cutaneous melanoma: a population-based study of 8177 cases","volume":"150","author":"Mocellin","year":"2011","journal-title":"Surgery"},{"key":"R18-20230902","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1245\/s10434-014-4132-5","article-title":"Lymph-node ratio in patients with cutaneous melanoma: a multi-institution prognostic study","volume":"22","author":"Sandro","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"R19-20230902","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1245\/s10434-011-1741-0","article-title":"Therapeutic surgical management of palpable melanoma groin metastases: superficial or combined superficial and deep groin lymph node dissection","volume":"18","author":"Van der Ploeg","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"R20-20230902","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1245\/s10434-012-2401-8","article-title":"Therapeutic lymph node dissection in melanoma: different prognosis for different macrometastasis sites?","volume":"19","author":"Wevers","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"R21-20230902","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ejca.2003.07.004","article-title":"Final results of the EORTC 18871\/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3\u2009mm) or regional lymph node metastasis","volume":"40","author":"Kleeberg","year":"2004","journal-title":"Eur J Cancer"},{"key":"R22-20230902","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S0140-6736(05)67482-X","article-title":"Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb\/III melanoma (EORTC 18952): randomised controlled trial","volume":"366","author":"Eggermont","year":"2005","journal-title":"Lancet"},{"key":"R23-20230902","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)61033-8","article-title":"Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial","volume":"372","author":"Eggermont","year":"2008","journal-title":"Lancet"},{"key":"R24-20230902","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1200\/JCO.2008.17.1579","article-title":"Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma","volume":"27","author":"O\u2019Day","year":"2009","journal-title":"J Clin Oncol"},{"key":"R25-20230902","first-page":"303","article-title":"A formula to estimate the approximate surface area if height and weight be known. 1916","volume":"5","author":"Du Bois","year":"1989","journal-title":"Nutrition"},{"key":"R26-20230902","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1109\/TAC.1974.1100705","article-title":"A new look at the statistical model identification","volume":"19","author":"Akaike","year":"1974","journal-title":"IEEE Trans Automat Contr"},{"key":"R27-20230902","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Melanoma Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00008390-201806000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T03:23:53Z","timestamp":1693625033000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008390-201806000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/cmr.0000000000000433","relation":{},"ISSN":["0960-8931"],"issn-type":[{"value":"0960-8931","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}